University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Biochemistry & Molecular
Biology

Biochemistry & Molecular Biology

4-2010

MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and
matrix-metalloproteinase-2 in prostate cancer cells.
Robert Steele
Saint Louis University

Justin L. Mott
University of Nebraska Medical Center, justin.mott@unmc.edu

Ratna B. Ray
Saint Louis University

Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles
Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons

Recommended Citation
Steele, Robert; Mott, Justin L.; and Ray, Ratna B., "MBP-1 upregulates miR-29b that represses Mcl-1,
collagens, and matrix-metalloproteinase-2 in prostate cancer cells." (2010). Journal Articles: Biochemistry
& Molecular Biology. 13.
https://digitalcommons.unmc.edu/com_bio_articles/13

This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

Original Article

MBP-1 Upregulates miR-29b,
Which Represses Mcl-1, Collagens,
and Matrix Metalloproteinase-2 in
Prostate Cancer Cells

Genes & Cancer
1(4) 381–387
© The Author(s) 2010
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1947601910371978
http://ganc.sagepub.com

Robert Steele1, Justin L. Mott2, and Ratna B. Ray1,3,4

Abstract
c-myc promoter binding protein (MBP-1) is a multifunctional protein known to regulate expression of targets involved in the malignant phenotype. We
have previously demonstrated that exogenous expression of MBP-1 inhibits prostate tumor growth, although the mechanism of growth inhibition is not
well understood. We hypothesized that MBP-1 may modulate microRNA (miRNA) expression for regulation of prostate cancer cell growth. In this study,
we demonstrated that exogenous MBP-1 upregulates miR-29b by 5- to 9-fold in prostate cancer cells as measured by real-time quantitative reverse
transcription polymerase chain reaction. Subsequent studies indicated that exogenous expression of miR-29b inhibited Mcl-1, COL1A1, and COL4A1.
Furthermore, a novel target with potential implications for invasion and metastasis, matrix metallopeptidase-2 (MMP-2), was identified and confirmed to
be a miR-29b target in prostate cancer cells. Together, these results demonstrated that exogenous expression of miR-29b regulates prostate cancer cell
growth by modulating antiapoptotic and prometastatic matrix molecules, implicating the therapeutic potential of miR-29b for prostate cancer inhibition.
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Introduction
Prostate cancer is the most commonly diagnosed cancer in
men and one of the leading causes of cancer death in the
United States.1 Although prostate cancer is frequently curable in its early stage by surgical or radiation ablation, many
patients present with locally advanced or metastatic disease
for which there are currently no curative treatment
options.2,3 Docetaxel-based chemotherapy has recently
been introduced for the treatment of metastatic prostate
cancer, following demonstration of its survival benefit in
advanced hormone-resistant prostate cancer patients.4,5
However, additional effective therapies with more favorable adverse effect profiles that can cure localized tumors
and prevent their metastasis are urgently needed.
Tumor suppressors regulate diverse pathways to block
tumor growth. We have shown previously that intratumor
injection of c-myc promoter binding protein (MBP-1) inhibits prostate tumor growth in xenograft nude mice and induces
cell death in a number of cancer cells without affecting
the normal cell growth.6-8 MBP-1 was originally described
to bind to and repress c-myc promoter function,9 but
subsequent investigation has demonstrated that the tumor
suppressor function of MBP-1 is not solely dependent on
c-myc repression.7,10,11 However, the mechanism of MBP-1–
mediated inhibition of prostate cancer cell growth is poorly
understood. We hypothesized that MBP-1 could exert its

antitumor action by differentially regulating expression of
microRNA (miRNA). miRNA are transcribed genes processed to single-stranded regulatory RNA of ~22 nucleotides.12 Mature miRNA repress protein expression primarily
through base pairing of a seed region with the 3′ untranslated
region (UTR) of the target mRNA leading to inhibition of
translation and/or mRNA degradation. An individual
miRNA is capable of regulating dozens of distinct mRNAs,
and together the >650 human miRNA are believed to modulate more than one-third of the mRNA species encoded in
the genome.13 Some miRNAs play a role in growth control
or apoptosis, providing a mechanistic underpinning for the
relation between miRNA and cancer.14-16 Moreover, miRNA
involved in specific networks, such as the apoptotic, proliferation, or receptor-driven pathways, could likely influence
the response to targeted therapies or to chemotherapy.
1

Department of Pathology, Saint Louis University, St. Louis, MO, USA
Mayo Clinic Center for Cell Signaling in Gastroenterology, Rochester,
MN, USA
3
Department of Internal Medicine, Saint Louis University, St. Louis, MO,
USA
4
Cancer Center, Saint Louis University, St. Louis, MO, USA
2

Corresponding Author:
Ratna B. Ray, Department of Pathology, Saint Louis University, 1100 South
Grand Boulevard, St. Louis, MO 63104
Email: rayrb@slu.edu

382

Genes & Cancer / vol 1 no 4 (2010)

PC3

DU145

AdMBP-1

dl312

0

2

4

6

8

10

miR-29b Expression (fold difference)

Figure 1. c-myc promoter binding protein (MBP-1) upregulates miR29b in prostate cancer cells. PC3 and DU145 cells were transduced
with control dl312 or AdMBP-1 for 48 hours. Total RNA was isolated,
and expression of miR-29b was measured using quantitative reverse
transcription polymerase chain reaction with a hydrolysis probe and
standardized to small nuclear RNA U6, which was used as the endogenous
control.The results are presented from 3 independent experiments, mean
± standard error. P < 0.001 by 1-way analysis of variance.

A differential expression of a subset of miRNA between
normal tissue and cancer and between cancers has been
noted.14,15 We identified a number of altered miRNA expression upon enforced MBP-1 expression and chose to examine
the function of miR-29b induction in prostate cancer cells,
which could be a downstream mediator of tumor suppression by MBP-1, because miR-29b plays a role in regulating
antiapoptotic and prometastatic proteins.
In this report, we have observed that MBP-1 upregulates
miR-29b in prostate cancer cells, which in turn inhibits
Mcl-1, matrix metallopeptidase-2 (MMP-2), and collagen
expression. These results also add to the growing list of
miRNAs that regulate tumor growth and provide a potential
mechanism for how MBP-1 suppresses tumor growth by
altering the expression of miRNA.

Results
MBP-1 upregulates miR-29b. MBP-1 has already been
shown to regulate the expression of multiple genes involved
in cell growth metastasis.7,10 Preliminary microarray analysis comparing the expression profile of miRNA between
prostate cancer PC3 cells transduced with AdMBP-1 or
control virus (dl312) showed an alteration of the expression
of 7 miRNA (R. Ray and R. Steele, manuscript in preparation). We chose to focus our investigation on miR-29b
because it was reported to be involved with the regulation
of cell proliferation, apoptosis, and migration. Quantitative
reverse transcription polymerase chain reaction (RT-PCR)
demonstrated miR-29b was significantly upregulated (6- to
8-fold) by enforced MBP-1 expression in PC3 and DU145
prostate cancer cell lines (Fig. 1).

miR-29b inhibits Mcl-1 in PC3 cells. Mcl-1 is an antiapoptotic Bcl-2 family member protein that is highly regulated
in normal cells, and when dysregulated, it contributes to
cancer. Enhanced Mcl-1 expression has been observed in
multiple human cancers, often in association with poor
prognosis, disease recurrence, or drug resistance.17 miR29b was shown to directly downregulate translation of the
Mcl-1 protein in cholangiocarcinoma cell lines.17 We tested
whether ectopic expression of miR-29b could alter Mcl-1
protein expression in prostate cancer cells. A significant
reduction in Mcl-1 protein was observed in the PC3 cell
line upon introduction of miR-29b as compared with control miRNA exposed PC3 cells (Fig. 2A). However, we
could not detect Mcl-1 expression in DU145 cells. Conversely, anti–miR-29b enhanced Mcl-1 expression in PC3
cells as compared with control anti-miR–treated cells (Fig.
2B). Densitometric scanning of protein bands suggested an
~60% reduction in Mcl-1 protein in the PC3 cells expressing miR-29b, whereas anti–miR-29b–expressing cells display enhanced Mcl-1 expression (~75%). The blots were
probed with actin for similar protein load. Densitometric
scanning results are presented after normalization of protein load. Furthermore, the signals from Figure 2A cannot
be compared with Figure 2B because they were from 2 different gels and exposed for different length of time.
To further determine if miR-29b inhibits Mcl-1 3′UTR,
we performed the luciferase assay by cotransfecting Mcl-1
(wt) or Mcl-1 (mt) with miR-29b precursor. In parallel, we
used the GAPDH 3′UTR, which is not a miR-29b target,
downstream of luciferase as a control. Our results showed
that expression miR-29b inhibits luciferase activity (70%)
of Mcl-1 (wt) but not the mutant form (Fig. 2C). Together,
these results suggest that miR-29b may have a cell growth
inhibitory effect by altering antiapoptotic protein expression in prostate cancer cells.
Collagens are directly targeted by miR-29b in prostate cancer cells. Recently, the miR-29 family was shown to inhibit
collagen mRNA expression in nasopharyngeal carcinomas
and osteoblast differentiation.18,19 To determine if miR-29b
regulated collagen expression in prostate cancer cell lines,
we used a firefly luciferase reporter containing the relevant
miR-29b binding sites (COL1A1, COL3A1, and COL4A1)
in the luciferase 3′UTR. In parallel, we used the GAPDH
3′UTR, which is not a miR-29b target, downstream of
luciferase as a control. Prostate cancer cells were transfected with these constructs with or without miR-29b mimic
transfection. The 3′UTRs of all of these 3 candidate target
genes (collagen 1A1, 3A1, and 4A1) elicited significantly
decreased luciferase activities in miR-29b mimic transfected cells (Fig. 3). As expected, we did not observe
an inhibition of GAPDH 3′UTR. Mutant 3′UTRs of all of
these 3 candidate target genes (nucleotide substitutions
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disrupting the miR-29b binding sites)
was also used. miR-29b did not alter
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did not alter the luciferase activity of
COL1A1, COL3A1, and COL4A1.

120
100
80
60
40
20
0

PC3

PC3 + anti-miR-29b

B

Mcl-1
Actin

Relative Expression of Mcl-1 (%)

Control

miR-29b

200
180
160
140
120
100
80
60
40
20
0
Control

anti-miR-29b

C
Mcl-1(mt)

Mcl-1(wt)

GAPDH

0

20

40

60

80

100

120

Relative Luciferase Expression

Figure 2. miR-29b modulates Mcl-1 expression. (A) Exogenous expression of miR-29b inhibits Mcl-1
expression in PC3 cells. Cells transfected with control miRNA, or miR-29b, were analyzed for Mcl-1
protein expression by Western blot using specific antibody.The blot was reprobed with actin antibody
to compare protein load. (B) Anti–miR-29b upregulates Mcl-1 expression in PC3 cells. PC3 cells were
transfected with control or anti–miR-29b. Cell lysates were analyzed by Western blot for expression
of specific proteins as described in A. Densitometric scanning of protein bands suggested a ~60%
reduction in Mcl-1 protein in PC3 cells expressing miR-29b, whereas anti–miR-29b–expressing cells
display enhanced Mcl-1 expression (~75%). The blots were probed with actin for similar protein load.
Densitometric scanning data are presented after normalization of protein load. (C) DU145 cells were
cotransfected with Mcl-1–derived 3′UTR insert (Mcl-1 wt) or luciferase with the mutated insert
at 3′UTR (Mcl-1 mt) and miR-29b expression plasmid DNAs. GAPDH 3′UTR luciferase construct
was used as an additional control. Luciferase activity was measured after 48 hours of transfection.
Luciferase activity from GADPH 3′UTR-transfected cells was arbitrarily set as 100%. The results are
presented as mean ± standard error from 3 independent experiments. P < 0.001 by 1-way analysis of
variance.

miR-29b inhibits collagen mRNA
expression in prostate cancer cells. To
test whether miR-29b indeed regulates the levels of the candidate target
mRNAs, we transfected miR-29b
mimic into PC3 cells. Cells were also
transfected in parallel with a control
mimic miRNA. In PC3 cells, 2 potential miR-29b target mRNAs were
reduced significantly by miR-29b
mimic transfection: COL1A1 and
COL4A1 (Fig. 4). Collagen 3A1
mRNA expression was undetectable
in PC3 cells, so its inhibition could
not be determined. The reason for
lack of collagen 3A1 mRNA in PC3
cells is not clear at present. Specifically, COL1A1 mRNA levels were
35% of control levels, whereas
COL4A1 mRNA levels were reduced
to 25%. Similar results were obtained
when PC3 cells were transduced with
AdMBP-1 (data not shown).
miR-29b inhibits MMP-2 expression.
MMP-2, a zymogen requiring proteolytic activation for catalytic activity,
has been implicated broadly in invasion and metastasis of many cancer
model systems, including prostate
cancer.20-22 MMP-2 has been shown
to be activated by collagen type 1,23 and
once activated, it degrades type 4 collagen in the basement membrane. Using
the Targetscan computer prediction
method, a putative miR-29b target
site in MMP-2 3′UTR was noted
(Fig. 5A). To examine whether miR29b inhibits MMP-2 expression, we
performed Western blot analysis in
control or miR-29b mimic transfected PC3 cells. Our results demonstrated a significant downregulation
of pro-MMP-2 in miR-29b–transfected PC3 cells (Fig. 5B). To determine
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Figure 3. miR-29b inhibits expression of luciferase with 3′UTRs derived
from its target genes. 3′UTR of target genes containing miR-29b–binding
sites were cotransfected with miR-29b mimic into prostate cancer cells.
Luciferase activity was measured after 48 hours of transfection. Luciferase
activity from GADPH 3′UTR transfected cells was arbitrarily set as 100%.
The results are presented as mean ± standard error from 3 independent
experiments. P < 0.001 by 1-way analysis of variance.

Figure 5. miR-29b targets matrix metallopeptidase-2 (MMP-2) and
represses pro–MMP-2 protein expression. (A) Computational analysis of
the MMP-2 3′UTR revealed a single putative miR-29b binding site with base
complementarity at positions 2 to 8 relative to the miR-29b 5′ terminus.
This putative binding site retains perfect conservation in the MMP-2 3′UTR
of human, primate, mouse, rat, and dog genomes.The miR-29b target region
of MMP-2 (NM_004530; isoform a) is indicated, with numbering from
the 1st nucleotide of the MMP-2 cDNA. (B) PC3 cells transfected with
control miRNA or miR-29b were analyzed for MMP-2 protein expression
by Western blot. The blot was reprobed with actin antibody to compare
protein load. Densitometric analysis indicated 80% inhibition of pro–MMP-2
protein expression. Blot is representative of 3 independent experiments.
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miR-29b, or both. Together, this result suggested that miR29b mediated pro-MMP-2 inhibition may serve as an additional layer of repression of MMP-2 function.
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Figure 4. miR-29b downregulates collagen mRNA expression. PC3 cells
transfected with control miRNA and miR-29b precursor for 48 hours.Total
RNA was isolated and COL1A1 and COL4A1 mRNA was quantified using
reverse transcription quantitative polymerase chain reaction. GAPDH was
used as an internal control and normalized for relative mRNA expression.
mRNA from control miRNA transfected cells was arbitrarily set as 100%.
The result presented was the mean from 3 independent experiments. P <
0.001 by 1-way analysis of variance.

the effect of miR-29b on MMP-2 mRNA level, total RNA
was isolated from PC3 cells transiently or stably transfected
with the mimic miR-29b or miR-29b expression construct.
Control miR was used in parallel. MMP-2 message was
quantitated by real-time RT-PCR. We did not observe a significant difference in mRNA level between control and
cells expressing miR-29b. Therefore, it appears that miR29b does not affect MMP-2 mRNA expression. On the
other hand, MMP-2 promoter activity was downregulated
by MBP-1 in a dose-dependent manner.10 Thus, these cancer-relevant targets could be repressed directly by MBP-1,

Discussion
miRNAs play a role in growth control or apoptosis, and a
differential expression of a subset of miRNA between normal
tissue and cancer and between cancers has been noted.14-16
We hypothesized that MBP-1, a transcriptional co-repressor
that regulates the expression of multiple genes, might directly
or indirectly regulate expression of miRNA that modulate the
cancer phenotype. Indeed, we have demonstrated that MBP-1
stimulates miR-29b expression in 2 prostate cancer cell lines.
miR-29b is of interest because it is involved with regulation
of apoptosis and prometastatic molecules with which MBP-1
was already implicated. Preliminary study also suggested
that the basal expression level of miR-29b is decreased in 3
of 4 prostate cancer specimens examined as compared with
nontumorigenic benign prostatic hyperplasia specimens (R.
Ray and G. Deng, unpublished observation). The salient
findings of the current study address the molecular mechanisms whereby the MBP-1/miR-29b axis could regulate
prostate cancer malignant behaviors. Specifically, in prostate
cancer cell lines, the MBP-1–induced miR-29b regulates 1)
Mcl-1, 2) collagens, and 3) MMP-2. Each of these targets
will be addressed below.
The antiapoptotic protein Mcl-1 is frequently overexpressed in cancers by various mechanisms, including
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Figure 6. A schematic diagram showing the hypothetical cross-regulation
of c-myc promoter binding protein (MBP-1), miR-29b, Mcl-1, collagen, and
matrix metallopeptidase-2 (MMP-2) in inhibition of prostate cancer cell
growth and invasion. The transcriptional co-repressor MBP-1 inhibits
MMP-2 activation while also inducing miR-29b. miR-29b acts to repress
Mcl-1, collagens, and pro–MMP-2 protein expression. Type I collagen
normally promotes MMP-2 activation; thus, the combined repression
of type I collagen and pro–MMP-2, plus MBP-1–dependent inhibition of
MMP-2 activation, efficiently prevents its activation. Mcl-1 targeting by
miR-29b meanwhile limits cellular survival and thus tumor growth.

genomic amplification,24 transcriptional induction, posttranscriptional regulation,25 and loss of microRNA function.26 Mcl-1 protein is found at elevated levels in prostate
cancer,27 with more Mcl-1–positive cells in Gleason grade 8
to 10 tumors than lower grade tumors.28 Furthermore,
Mcl-1 induction in prostate cancer cells by the inflammatory cytokine IL-6 provides resistance to apoptosis.29 Thus,
Mcl-1 in prostate cancer, as in other malignancies, is a central mediator of the resistance to apoptosis. In this study, we
have observed that MBP-1–induced miR-29b inhibits
Mcl-1 protein levels, consistent with previous work.26
Increased extracellular levels of collagens have been
shown to induce increased invasiveness in culture and
increased metastasis in animal models. Similarly, increased
levels of collagens have been associated with an increased
likelihood of clinical metastasis of multiple human solid
tumors.30 Using laser capture isolated tumor cells, Sengupta
and others18 have shown that nasopharyngeal carcinoma
cells upregulate collagen mRNAs. Collagen type I contributes to invasiveness and metastasis in pancreatic cancer.31,32
Furthermore, in prostate cancer, the alpha-1 chain of type
IV collagen (COL4A1) is produced by malignant cells and
increased with increasing tumor grade,33 suggesting a role
in tumor pathology. Thus, our finding that miR-29b regulates COL1A1, COL3A1, and COL4A1 is consistent with
enhanced collagen production upon miR-29b repression,
potentially facilitating metastatic activity. Conversely,
MBP-1 induction of miR-29b and inhibition of collagen
production may present a useful therapeutic goal.
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MMP-2 is a key enzyme in the process of extracellular
matrix remodeling involved in tumor invasion and metastasis.
In hepatocellular carcinomas, increased collagen I mRNA
levels were strongly associated with those of MMP-2.34
Collagen I induces MMP-2 activation in breast cancer cells
and hepatocellular carcinoma.24,34 We demonstrated here
that MMP-2 is a predicted target of miR-29b, and we
recently showed that MBP-1 expression reduced active
MMP-2 in breast cancer cells.10 Here, we have observed
that miR-29b inhibits pro–MMP-2 protein expression in
PC3 cells. Although MMP-2 activation is directly inhibited
by MBP-1, inhibition by miR-29b could be another mechanism, and a working model is proposed (Fig. 6). This possibility is supported by the observation that expression in
MBP-1 in PC3 cells upregulated miR-29b and enforced
miR-29b expression downregulated MMP-2. MMP-2 is a
protein with significance in prostate cancer, as MMP-2–
mediated degradation of type IV collagen in the basement
membrane may promote metastatic invasion. Thus,
although both the alpha-1 chain of collagen IV and the type
IV metalloproteinase MMP-2 are targeted by miR-29b, the
end result of low miR-29b may be increased turnover of
basement membranes consistent with active remodeling of
the extracellular matrix.
The mechanism by which MBP-1 induces miR-29b was
not investigated. As miR-29b is repressed by c-myc expression,35 it is plausible that MBP-1 decreases c-myc in PC3
and DU145 cells, allowing the de-repression of mir-29b.
Further experiments will be necessary to confirm this
hypothesis. In conclusion, our results demonstrated a mechanistic insight into miRNA function in prostate cancer cells.
We have shown that miR-29b targets antiapoptotic and prometastatic molecules in prostate cancer cells for regulation
of growth. These results suggest that further preclinical trials are needed to establish whether miR-29b could also be
useful alone or in combination with conventional chemotherapeutics or conventional targeted agents for the treatment of prostate cancer.

Materials and Methods
Cell lines and cell culture. PC3 and DU145 cell lines were
purchased from American Type Culture Collection and
maintained in DMEM containing 10% fetal bovine serum,
100 U/mL penicillin, and 100 µg/mL streptomycin in a
humidified CO2 incubator.
Western blot analysis. PC3 and DU145 cells were transduced with a replication deficient adenoviral vector expressing MBP-1 (AdMBP-1; 7) or dl312 control virus, and cell
lysates were prepared 48 hours postinfection in 2x SDSsample buffer. Similarly, cells were transfected with miR29b mimic or control miRNA (random sequence Pre-miR
molecules; Applied Biosystems, Foster City, CA), and cells
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lysates were prepared 48 hours posttransfection. In addition,
anti–miR-29b (Applied Biosystems) was transfected and
cell lysates prepared for immunoblot analysis at 48 hours.
Mcl-1 or MMP-2 expression was analyzed by Western blot
using specific rabbit polyclonal antisera (Santa Cruz Biotechnology, Santa Cruz, CA), followed by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ) as
described previously.10 Relative expression level was determined by densitometry, normalized to the expression of
actin (mouse monoclonal; Santa Cruz Biotechnology).
Quantitative real-time RT-PCR. miRNA expression was
determined by isolating total RNA using TRIzol reagent
(Invitrogen, Carlsbad, CA). Total RNA (200 ng) was reverse
transcribed using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems) with miRNA-specific
primers. To quantify the miRNA levels, the 7500 Real-Time
System (Applied Biosystems) was used in conjunction with
gene-specific TaqMan assay kits (Applied Biosystems) for
miR-29b and U6. U6 was used as an endogenous control to
normalize expression. Relative miR-29b expression and
standard error were calculated by the supplied 7500 RealTime System software.
Luciferase assay. Luciferase reporter constructs containing the putative miR-29b binding sites from Mcl-1,26
Col1A1, Col3A1, and Col4A118,19 were as described previously. Constructs were co-transfected into PC-3 or DU145
cells cultured in 12-well plates using Lipofectamine 2000.
Briefly, 30 nM miRNA mimic or control miRNA was transfected with 0.6 µg of the pMIR 3′UTR clones. Luciferase
activity was measured 48 hours posttransfection using
equal amount of protein as described previously.10
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